ORXOF (Orexo AB) Stock Based Compensation: $1.33 Mil (TTM As of Mar. 2026)


ORXOF Orexo AB ORXOF
34 GF Score
Price $2.10
GF Value $0.68
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Orexo AB Stock Based Compensation?

Orexo AB ORXOF 34 Stock Based Compensation is $1.33 Mil as of Mar. 2026. GuruFocus rates ORXOF with a GF Score™ of 34/100 and a GF Value™ of $0.68 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Orexo AB's Stock Based Compensation for the three months ended in Mar. 2026 was $0.34 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $1.33 Mil.

Orexo AB Stock Based Compensation Related Terms

Orexo AB Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Orexo AB's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orexo AB Stock Based Compensation Chart

Orexo AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.17 -0.01 0.00 0.00 0.00

Orexo AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 1.45 0.49 -0.95 0.34
ORXOF
34GF Score
Orexo AB ORXOF
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orexo AB Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.33 Mil.

What does a Stock Based Compensation of $1.33 Mil mean?
Orexo AB (ORXOF) has a Stock Based Compensation of $1.33 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Orexo AB and its competitors.
Is Orexo AB's Stock Based Compensation too high?
Orexo AB's current Stock Based Compensation is $1.33 Mil. Overall, Orexo AB has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orexo AB's Stock Based Compensation compare to ZTS?
Orexo AB's Stock Based Compensation of $1.33 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Orexo AB and its competitors. Orexo AB's current Stock Based Compensation is $1.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orexo AB stock overvalued right now?
Based on GuruFocus' analysis, Orexo AB (ORXOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.68, compared to a current price of $2.10 — trading 208.8% above its estimated fair value. The current Stock Based Compensation is $1.33 Mil. Orexo AB's overall GF Score™ is 34/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Orexo AB (ORXOF), the current Stock Based Compensation is $1.33 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orexo AB (ORXOF) Overvalued in 2026?

Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued. The current stock price of $2.10 is trading 208.8% above its estimated GF Value™ of $0.68. GuruFocus considers Orexo AB to be Significantly Overvalued.

Key valuation signals for ORXOF:

  • Stock Based Compensation: $1.33 Mil
  • GF Value™: $0.68 vs. price of $2.10 (208.8% above fair value)
  • GF Score™: 34/100 with 7 warning signs

No single metric tells the full story. See the ORXOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orexo AB Business Description

Address Virdings alle 22, Uppsala, SWE, 75105
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
34GF Score

Get the complete analysis for ORXOF

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.10
Price
$0.68
GF Value